The New Obesity Drugs: What Cardiac Practitioners Need to Know
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
The New Obesity Drugs: What Cardiac Practitioners Need to Know
-
Narrated by:
-
By:
About this listen
Please join our special guest Dr. Ian Neeland from University Hospitals in Cleveland, to discuss the intersection of obesity and cardiovascular disease, and specifically the roles of the new agents semaglutide and tirzepatide. We discuss the recent data on cardiovascular outcomes with these agents, assessing patient candidacy, and tips for initiating and monitoring therapy. We also reviewed the complementary role of bariatric surgery and pharmacotherapy to improve cardiac outcomes.
For more information, see the SELECT study.
For more information about the UH CINEMA program, click on this link.
Please subscribe to receive updated episodes automatically! Visit https://www.ohioacc.org/cardiohio-podcast/.
“Upbeat Party” by scottholmesmusic.com
activate_mytile_page_redirect_t1
What listeners say about The New Obesity Drugs: What Cardiac Practitioners Need to Know
Average Customer RatingsReviews - Please select the tabs below to change the source of reviews.
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.